Effects of diosgenin on the skeletal system in rats with experimental type 1 diabetes - 28/08/20
pages | 11 |
Iconographies | 7 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | Diosgenin did not counteract the diabetes-induced metabolic disorders in rats. |
• | Diosgenin did not affect bone mineralization and strength in diabetic rats. |
• | Diosgenin slightly improved cancellous bone microstructure in diabetic rats. |
• | Diosgenin counteracted the effect of diabetes on the growth plate in rats. |
Abstract |
There is a great interest in substances of plant origin, which may exert health-promoting activities in diabetes and its complications. Previous studies suggested that diosgenin may favorably affect both glucose metabolism and osteoporosis. The aim of the study was to investigate the effects of diosgenin on the skeletal disorders induced by experimental type 1 diabetes (T1D) in rats. The experiments were performed on 3-month-old female rats, divided into three groups: I – healthy control rats, II – streptozotocin-induced diabetic control rats, III – diabetic rats receiving diosgenin. T1D was induced by a single streptozotocin injection (60 mg/kg i.p.). Diosgenin administration (50 mg/kg/day p.o.) started two weeks later and lasted four weeks. Serum bone turnover markers and other biochemical parameters, bone mass and mineralization, mechanical properties and histomorphometric parameters were examined. Diabetes induced profound metabolic disturbances and disorders of cancellous bone microarchitecture and strength. Diosgenin did not favorably affect the serum bone turnover markers and other biochemical parameters, bone mass, mineralization and mechanical properties in the diabetic rats. However, it counteracted the effect of diabetes on the growth plate and cancellous bone microarchitecture in the distal femur, indicating some limited beneficial influence on the skeleton.
Le texte complet de cet article est disponible en PDF.Abbreviations : ALP, ALT, ANOVA, AOPP, ASBMR, AST, BMD, BV/TV, CTX-I, DIOS, GLP-1, GLUT-4, HFD, IGF-1, i.p., LDH, LSD, Ma.Ar, Ma.Ar/Tt.Ar, MANOVA, Tt.Ar, PCA, p.o., PPAR-γ, SEM, SGLT-1, SGLT-2, STZ, T1D, T2D, TAC, Tb.N, Tb.Sp, Tb.Th
Keywords : Diosgenin, Diabetes, Rat, Skeletal system, Osteoporosis
Plan
Vol 129
Article 110342- septembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?